Cue Biopharma (CUE) Other financing activities (2017 - 2022)
Cue Biopharma's (CUE) quarterly Other financing activities came in at -$1000.0 in Q4 2022, down 100.7% quarter-over-quarter from $142000.0 in Q1 2022.
Cue Biopharma (CUE) Other financing activities (2017 - 2022) Analysis & Trends
Cue Biopharma has disclosed Other financing activities across 3 years of filings, most recently posting -$1000.0 for Q4 2022.
- Other financing activities for Q4 2022 came in at -$1000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2023 was -$1000.0 (down 100.7% YoY), and the FY2022 annual result was $141000.0, changed N/A from the prior year.
- Other financing activities came in at -$1000.0 for Q4 2022 at Cue Biopharma, down from $142000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $509000.0 in Q2 2018 to a low of -$1.1 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Cue Biopharma | 581.16 Mn | 553.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -1,000.00 |
| Dec 31, 2022 | -1,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Mar 31, 2022 | 142,000.00 |
| Dec 31, 2018 | -236,272.00 |
| Dec 31, 2018 | -236,272.00 |
| Jun 30, 2018 | 509,000.00 |
| Jun 30, 2018 | 509,000.00 |
| Mar 31, 2018 | -1.06 Mn |
| Mar 31, 2018 | -1.06 Mn |
| Dec 31, 2017 | 4.27 Mn |
| Dec 31, 2017 | 4.27 Mn |
| Sep 30, 2017 | -8,000.00 |
| Sep 30, 2017 | -8,000.00 |
| Mar 31, 2017 | -101,000.00 |
| Mar 31, 2017 | -101,000.00 |